Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Observational

Prevalence of Lower and Upper Incisor Periodontal Phenotypes and Risk Indicators.

NCT06981871 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2025-06-01
Last updated
2026-09-18

Condition(s) studied

GingivaPhenotype

Investigational drug(s) / intervention(s)

Evaluation of the gingival phenotype of the incisors in the upper and lower jaws

Evaluation of the gingival phenotype of the incisors in the upper and lower jaws: Assessment of gingival thickness (Kan et al 2015) and keratinised tissue height of the incisors with UNC-15 peridontal probe (Hu-Freidy, USA) and clinical photography.

Study summary

The determination of the periodontal phenotype is an essential part of the periodontal diagnostic process, which must guide not only treatment but also prognosis (Kim et al. 2020).

This determination is based on the clinical assessment of 3 individual variables: gingival height/thickness and alveolar bone cortical thickness. Although these anatomical characteristics are genetically determined, they are also influenced by numerous acquired, endogenous or exogenous factors that can act at a general and/or local level. The periodontal phenotype is therefore specific to an individual and its 3 components vary over time according to the dental sectors and sites of each individual. For example, the morphology of this phenotype varies according to whether the gingiva is thick or thin, high or reduced, and the bone cortex is thick or thin, with all possible combinations. Clinicians need to know the distribution of these different types of phenotypes, particularly in the aesthetic areas they are concerned with, in order to better identify the most fragile ones in the face of the multiple daily stresses to which the periodontium may be subjected: muscular force, dental plaque, oral hygiene manoeuvres, parafunctionality, dental procedures....

However, studies on the prevalence of the periodontal phenotype are limited and mainly concern Asian, Indian and American populations, with very few studies on European populations. Main objective: To assess the prevalence of periodontal phenotypes in the upper and lower incisors of French subjects, according to tooth type and at the individual level. Secondary objective: Identification of potential risk indicators in relation to the type of periodontal phenotype."

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age (18 years old or older), * Dental student on the university hospitals of Nice and Nancy. * Social security affiliate. * Systemically healthy. * Healthy and intact periodontium. * Informed consent. Exclusion Criteria: * Pregnancy. * Under any regular medical treatment. * Active periodontal disease. * Enduring orthodontic treatment. * Periodontal surgery in the mandibulary anterior region. * Non consent patient. * Patient under judgment trials.

Primary outcome measure(s)

  • Prevalence of gingival phenotypes (gingival thickness ) — At the inclusion
    Assessment of gingival thickness
  • Prevalence of gingival phenotypes (keratinised tissue height) — At the inclusion
    Evaluation of keratinised tissue height of the lower and upper incisors with UNC-15 peridontal probe (mm) and clinical photography.
  • Prevalence of gingival phenotypes (Photography) — At the inclusion
    Description of the gingiva

Trial sites (1)

FacilityCityRegionStatus
CHU NICE Nice Alpes Maritimes

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06981871 on ClinicalTrials.gov ↗ ← All trials in France